Meeting the Demand for Unrelated Donors in the Midst of the COVID-19 Pandemic: Rapid Adaptations by the National Marrow Donor Program and Its Network Partners Ensured a Safe Supply of Donor Products
- PMID: 33830022
- PMCID: PMC7834500
- DOI: 10.1016/j.jtct.2020.10.014
Meeting the Demand for Unrelated Donors in the Midst of the COVID-19 Pandemic: Rapid Adaptations by the National Marrow Donor Program and Its Network Partners Ensured a Safe Supply of Donor Products
Abstract
The impact of the coronavirus disease 2019 (COVID-19) pandemic on hematopoietic cell transplant (HCT) donor registries and transplant center (TC) practices is underreported. This article reports on the National Marrow Donor Program (NMDP) Be The Match Registry and its coordinating the provision of unrelated donor (URD) products to domestic and international TCs during the initial 3 months of the COVID-19 pandemic (March through May 2020). Specifically, NMDP data are presented for disease indications for transplant, URD search volumes and availability, graft requests and processing, courier utilization and performance, and conversion rates from formal donor search and workup to graft collection and shipment. Data following the onset of COVID-19 are compared to the immediate 3 months prior to the COVID-19 pandemic (December 2019 through February 2020) and the same quarter 1 year prior to COVID-19 (March through May 2019). During the initial onset of COVID-19 and compared to 1 year prior, TCs requested and the NMDP performed less donor searches. More multiple URD and direct to workup requests were processed by the NMDP, which likely reflected reductions in donor availability. Yet TCs continued to perform allogeneic transplants for acute disease indications like acute leukemia and myelodysplasia, using more cryopreserved grafts than before COVID-19. In comparison to prepandemic patient cycle conversion rates and durations, the NMDP was able to convert patient cycles at nearly the same or higher rates and in similar or shorter periods of time. Last, despite significant challenges caused by the pandemic, including interruptions in domestic courier services and travel restrictions, graft products were delivered to and received by TCs in similar periods of time than before COVID-19. Taken together, these data show that NMDP service line operations continued to function effectively during the early phases of the COVID-19 pandemic, ensuring requests for and delivery of URD products to domestic and international allogeneic HCT recipients.
Keywords: Bone marrow transplant; COVID-19; Coronavirus; Donor registry; Donor search; Graft; HLA matching; National Marrow Donor Program; Peripheral blood transplant; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Umbilical cord blood; Unrelated donor.
Copyright © 2020 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.
Figures



Similar articles
-
Demand and usage of unrelated donor products for allogeneic haematopoietic cell transplantation during the COVID-19 pandemic: A Canadian Blood Services Stem Cell Registry analysis.Vox Sang. 2022 Sep;117(9):1121-1125. doi: 10.1111/vox.13294. Epub 2022 May 18. Vox Sang. 2022. PMID: 35583125 Free PMC article.
-
Neither COVID-19, nor cryopreservation, prevented allogeneic product infusion: A report from the National Marrow Donor Program.Front Immunol. 2022 Sep 20;13:937900. doi: 10.3389/fimmu.2022.937900. eCollection 2022. Front Immunol. 2022. PMID: 36203566 Free PMC article.
-
The Effect of Donor Graft Cryopreservation on Allogeneic Hematopoietic Cell Transplantation Outcomes: A Center for International Blood and Marrow Transplant Research Analysis. Implications during the COVID-19 Pandemic.Transplant Cell Ther. 2021 Jun;27(6):507-516. doi: 10.1016/j.jtct.2021.03.015. Epub 2021 Mar 22. Transplant Cell Ther. 2021. PMID: 33865804 Free PMC article.
-
Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR.Blood. 2019 Sep 19;134(12):924-934. doi: 10.1182/blood.2019001212. Epub 2019 Jul 10. Blood. 2019. PMID: 31292117 Free PMC article. Review.
-
Twenty years of unrelated donor bone marrow transplantation for pediatric acute leukemia facilitated by the National Marrow Donor Program.Biol Blood Marrow Transplant. 2008 Sep;14(9 Suppl):16-22. doi: 10.1016/j.bbmt.2008.05.019. Biol Blood Marrow Transplant. 2008. PMID: 18721776 Review.
Cited by
-
Demand and usage of unrelated donor products for allogeneic haematopoietic cell transplantation during the COVID-19 pandemic: A Canadian Blood Services Stem Cell Registry analysis.Vox Sang. 2022 Sep;117(9):1121-1125. doi: 10.1111/vox.13294. Epub 2022 May 18. Vox Sang. 2022. PMID: 35583125 Free PMC article.
-
Are We Making PROGRESS in Preventing Graft-versus-Host Disease and Improving Clinical Outcomes? Impact of BMT CTN 1301 Study Results on Clinical Practice.Transplant Cell Ther. 2022 Aug;28(8):419-425. doi: 10.1016/j.jtct.2022.05.002. Epub 2022 May 9. Transplant Cell Ther. 2022. PMID: 35550441 Free PMC article.
-
Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant Research.Transplant Cell Ther. 2023 Jun;29(6):346.e1-346.e10. doi: 10.1016/j.jtct.2023.03.007. Epub 2023 Mar 15. Transplant Cell Ther. 2023. PMID: 36924931 Free PMC article.
-
Secondary Impact of the Coronavirus Disease 19 Pandemic on Patients and the Cellular Therapy Healthcare Ecosystem.Transplant Cell Ther. 2022 Nov;28(11):737-746. doi: 10.1016/j.jtct.2022.07.020. Epub 2022 Jul 25. Transplant Cell Ther. 2022. PMID: 35902050 Free PMC article. Review.
-
Clinical impact of cryopreservation of allogeneic hematopoietic cell grafts during the onset of the COVID-19 pandemic.Blood Adv. 2023 Oct 10;7(19):5982-5993. doi: 10.1182/bloodadvances.2023009786. Blood Adv. 2023. PMID: 37036959 Free PMC article.
References
-
- Miller I.F., Becker A.D., Grenfell B.T., Metcalf C.J.E. Disease and healthcare burden of COVID-19 in the United States. Nat Med. 2020;26:1212–1217. - PubMed
-
- Galea S., Abdalla S.M. COVID-19 pandemic, unemployment, and civil unrest: underlying deep racial and socioeconomic divides. JAMA. 2020;324:227–228. - PubMed
-
- Algwaiz G., Aljurf M., Koh M., et al. Real-world issues and potential solutions in hematopoietic cell transplantation during the COVID-19 pandemic: perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. Biol Blood Marrow Transplant. 2020;26:2181–2189. - PMC - PubMed
-
- Ljungman P., Mikulska M., de la Camara R., et al. Correction: The challenge of COVID-19 and hematopoietic cell transplantation: EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy [e-pub ahead of print]. Bone Marrow Transplant. 2020 Nov;55(11):2071-2076. doi:10.1038/s41409-020-0919-0. Epub 2020 May 13. - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous